logo-loader

Admedus secures milestone payment for its unique technology from 4C Medical

Published: 01:21 03 Feb 2020 EST

Admedus Ltd - Admedus secures milestone payment for its unique technology from 4C Medical
4C Medical will benefit from this technology to optimise function and durability

Admedus Ltd (ASX:AHZ) has completed the technology transfer of its unique sterilisation method as part of its ADAPT tissue treatment process to 4C Medical Technologies, Inc.

4C Medical is a Minnesota-based developer of AltaValve, a minimally invasive device for mitral valve repair. The technology transfer follows 4C Medical validating the process.

4C Medical will now pay an additional $US1 million ($US 0.44 million previously received) to use the technology to sterilise the ADAPT tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve system device.

“Transformative healing advantages” of ADAPT

The 4C Medical implant utilises tissue processed by Admedus’ clinically superior ADAPT Tissue Engineering Process for the functioning leaflet component of its valve.

4C Medical will benefit from this technology to optimise function and durability.

Admedus chief executive officer Wayne Paterson said: “For the millions of patients suffering from Mitral Regurgitation, Admedus is proud to provide the transformative healing advantages of ADAPT treated tissue with demonstrated clinically superior performance over ten years.”

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

16 hours, 1 minute ago